Arcus Biosciences (NYSE: RCUS) has launched an underwritten public offering of its common stock, with all shares sold by the company. It will give underwriters a 30-day option to buy up to an additional 15% of the shares. Jefferies, Leerink Partners and TD Cowen are joint book-running managers. The offering follows new data from the ARC-20 study of casdatifan, an investigational kidney cancer drug. In first-line treatment, casdatifan plus zimberelimab showed 69% progression-free survival at 12 months, against 50% for the approved ipilimumab and nivolumab combination. In heavily pre-treated patients, casdatifan alone reached a 35-month median overall survival. Arcus expects to start the Phase 3 PEAK-20 trial in the fourth quarter of 2026.

Arcus Biosciences (NYSE:RCUS) now covered by JPMorgan Chase & Co. October 14, 2026 Key points. * JPMorgan initiated coverage of Arcus Biosciences with an "overweight" rating and a $41 price target, implying approximately 81.9% upside from the prior close. * Analyst sentiment is generally positive: 11 analysts rate the stock Buy, three Hold, and one Sell, producing a consensus "Moderate Buy" rating and an average price target of $38.55. * Arcus beat quarterly expectations with an adjusted loss of $0.72 per share versus the $0.89 estimate and revenue of $41 million, though revenue declined 74.4% year over year and the company remains unprofitable. * MarketBeat previews the top five stocks to own by November 1st. Stock analysts at JPMorgan Chase & Co. assumed coverage on shares of Arcus Biosciences (NYSE:RCUS - Get Free Report) in a report released on Wednesday, Benzinga reports. The firm set an "overweight" rating and a $41.00 price target on the stock. JPMorgan Chase & Co.'s price objective would suggest a potential upside of 81.87% from the company's previous close. A number of other research analysts have also weighed in on the stock. Cantor Fitzgerald reiterated an "overweight" rating on shares of Arcus Biosciences in a research note on Friday, September 11th. Wall Street Zen upgraded Arcus Biosciences from a "sell" rating to a "hold" rating in a research report on Saturday, October 3rd. TD Cowen began coverage on Arcus Biosciences in a research report on Wednesday, September 16th. They issued a "buy" rating for the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of Arcus Biosciences in a research note on Friday, July 17th. Finally, Morgan Stanley set a $23.00 price objective on Arcus Biosciences in a report on Monday, August 10th. Eleven equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $38.55. Arcus Biosciences price performance. RCUS opened at $22.54 on Wednesday. The company has a market capitalization of $2.87 billion, a price-to-earnings ratio of -5.78 and a beta of 0.94. The company has a quick ratio of 3.82, a current ratio of 3.82 and a debt-to-equity ratio of 0.22. The firm has a 50-day moving average price of $27.31 and a 200-day moving average price of $26.20. Arcus Biosciences has a twelve month low of $15.38 and a twelve month high of $31.74. Discover more MarketBeat All Access Stock Market News Stock Average Calculator Arcus Biosciences (NYSE:RCUS - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.72) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.89) by $0.17. The company had revenue of $41.00 million for the quarter, compared to analyst estimates of $21.98 million. Arcus Biosciences had a negative net margin of 393.16% and a negative return on equity of 89.54%. The company's revenue for the quarter was down 74.4% on a year-over-year basis. Equities analysts expect that Arcus Biosciences will post -3.53 EPS for the current year. Insider activity. In other news, CAO Alexander Azoy sold 2,827 shares of the company's stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $30.00, for a total value of $84,810.00. Following the completion of the transaction, the chief accounting officer directly owned 39,581 shares in the company, valued at approximately $1,187,430. This represents a 6.67% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 7.60% of the company's stock. Hedge funds weigh in on Arcus Biosciences. A number of large investors have recently modified their holdings of the company. BlackRock Inc. bought a new stake in Arcus Biosciences in the second quarter worth $506,113,000. Parkman Healthcare Partners LLC purchased a new stake in Arcus Biosciences during the second quarter valued at about $28,341,000. Bank of America Corp DE purchased a new stake in Arcus Biosciences during the second quarter valued at about $25,759,000. Bank of New York Mellon Corp bought a new position in shares of Arcus Biosciences during the second quarter valued at about $16,741,000. Finally, Renaissance Technologies LLC grew its stake in shares of Arcus Biosciences by 1,198.8% during the first quarter. Renaissance Technologies LLC now owns 424,700 shares of the company's stock valued at $9,174,000 after buying an additional 392,000 shares during the last quarter. 92.89% of the stock is owned by hedge funds and other institutional investors. About Arcus Biosciences. Arcus Biosciences, Inc is a biopharmaceutical company focused on discovering and developing medicines for the treatment of cancer. The company uses a proprietary research platform to develop small-molecule and antibody-based therapies designed to target biological mechanisms involved in tumor growth and immune-system regulation. Arcus' oncology pipeline has included investigational therapies such as zimberelimab, an anti-PD-1 antibody; domvanalimab, an anti-TIGIT antibody; quemliclustat, a CD73 inhibitor; and etrumadenant, an adenosine receptor antagonist. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Arcus Biosciences, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arcus Biosciences wasn't on the list. While Arcus Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow. Continue following MarketBeat